IMPERATIVE AND OBSTRUCTIVE URINATION DISORDERS IN PATIENTS WITH CHRONIC INFLAMMATORY DISEASES OF THE URINARY TRACT


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The estimation of functional parameters of the lower urinary tract in 116 patients with chronic cystitis and 51 patients with chronic nonobstructive pyelonephritis was performed. Urethral instability was revealed in 53 (45.68%) patients with chronic cystitis (mean age, 40.72 ± 14.45 years), detrusor overactivity - in 10 (8.62%, mean age, 45.55 ± 13.45 years) patients. Variations in detrusor pressure were 22.16 ± 15.8 cm H2O. Combination of urethral instability and detrusor overactivity was diagnosed in 26 (22.4%) patients of the study group (mean age, 65.16 ± 10.49 years). The maximum urethral pressure was 75.5 ± 21.44 cm H2O, variations in urethral pressure— 37.45 ± 17.44 cm H2O. Reduction in the maximum urinary flow rate less than 15 ml/s was detected in 47 (40.5%) patients. Signs of detrusor-sphincter dyssynergia were observed in 29 (25%) patients. After processing the urodynamic studies of patients with non-obstructive pyelonephritis, 20 (39.21%) patients with severe detrusor hypotension, 18 (35.29%) - with detrusor overactivity, 26 (50.98%) - with urethral instability were identified. Based on the results of the study, it was concluded that women's chronic inflammation in the bladder and kidneys may not be the cause but the consequence of functional disorders of the lower urinary tract infections associated with the disorders of the nervous regulation of these organs. Inflammation in the bladder wall against the background of dysfunction of the lower urinary tract, in turn, can support a dysfunction of the bladder and/or urethra. Drugs affecting the function of the sympathetic and parasympathetic elements of the autonomic nervous system can be used for the elimination of functional disorders of the lower urinary tract and improvement the functioning of these organs. Thus, the pathogenetic treatment of chronic cystitis should be based on the disruption of “vicious circle” dysfunction- inflammation. In view of these data, and due to the frequent detection of imperative and functional obstructive urination disorders, in addition, based on the neurophysiological concept of their occurrence, the use of α-adrenoblockers and M-anticholinergics agents is important in the treatment strategy with regard to patients with chronic recurrent cystitis and non-obstructive pyelonephritis.

Full Text

Restricted Access

References

  1. Лопаткин Н.А., Родоман В.Е., Ярмолинский И.С. и др. Предрасполагающие факторы возникновения пиелонефрита трансплантированной почки. В кн.: “Актуальные вопросы пересадки органов и тканей”. М., 1978. 16—18.
  2. Хайрлиев Г.З. Изменения мочевого пузыря при дизурии у женщин. Дисс. канд. мед. наук. М., 1990.
  3. Даренков А.Ф. Трансплантация почки в клинике. Сборник научных трудов. 2-й Моск. мед. ин-т. 1973. Т. 23. С. 53—56.
  4. Мартынова Н.В. Урологические аспекты трансплантации почки. Дисс. канд мед. наук. М., 1974.
  5. Colfry A.J., Schlegel J.U., Lindsey E.S. et al. Urological complications in renal transplantation. J. Urology. 1974;112:564—565.
  6. Dreikorn K., Horsch R., Rossler W. Chirurgisch-urologische Komplikationen nach Nierentransplantation. Urologe. 1982;21:S256—264.
  7. Barry J.M., Hatch D.A. Parallel incision unstented extravesical ureteroneocystostomy: follow up of 203 kidney transplants. J. Urology. 1985;134:249—251.
  8. Левин Е.И. Цистит у женщин: диагностика и лечение: Дисс. канд. мед. наук. М., 1999.
  9. Зайцев А.В. Диагностика и лечение интерстициального цистита у женщин. Дисс. д-ра мед. наук. М., 1999.
  10. Джавад-Заде М.Д., Державин В.М. Нейрогенные дисфункции мочевого пузыря. М.: Медицина. 1989. 101 — 137, 384.
  11. Исаков Ю. Ф. Хирургические болезни у детей. М., 1998. 327.
  12. Гаджиева З.К. Уродинамические исследования в диагностике и лечении нарушений мочеиспускания. Дисс. докт. мед. наук. М., 2009.
  13. Wyndaele J.J. Development and evaluation of the management of the neuropathic bladder. Paraplegia 1995;33:305.
  14. Gerridzen R.G., Thijssen A.M., Dehoux E. Risk factors for upper tract deterioration in chronic spinal cord injury patients. J. Urol. 1992;147:416.
  15. Лоран О.Б., Пушкарь Д.Ю., Тевлин К.П. Урология. 1998;6:24.
  16. Аляев Ю.Г., Григорян В.А., Гаджиева З.К. Расстройства мочеиспускания. М.: Литтерра, 2006. 208.
  17. Гаджиева З.К. Нарушения мочеиспускания. Под ред. Ю.Г. Аляева. М.: ГЭОТАР-Медиа, 2010. 176.
  18. Williams D., Chisholm G. Scientific foundations of urology. London. 1976;11:473.
  19. Davis B.J., Noble A., Chapple C.R. et al. Human Prostate-artery selectivity of tamsulosin, doxazosin and alfuzosin. Current opinions in CPNS investigational drugs (Chapple C.R., Chess-Williams R.). 1999;1(2):221—230.
  20. Ohtake A., Ukai M., Hatanka T. et al. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur. J. Pharmacol. 2004;492: 243—250.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies